IDEAYA Biosciences (IDYA) Accumulated Expenses (2018 - 2026)

IDEAYA Biosciences has disclosed Accumulated Expenses across 9 years of filings, most recently posting $6.2 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $6.2 million, up 26.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.2 million (up 26.39% YoY), and the FY2025 annual result was $11.2 million, down 63.11% from the prior year.
• Accumulated Expenses came in at $6.2 million for Q1 2026 at IDEAYA Biosciences, down from $11.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $45.3 million in Q3 2025 to a low of $2.6 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $7.4 million (2024), against an average of $13.3 million.
• Across the five-year window, Accumulated Expenses soared 554.81% in 2023 and sank 75.34% in 2024, its largest moves.
• IDEAYA Biosciences' Accumulated Expenses stood at $17.0 million in 2022, then tumbled by 58.97% to $7.0 million in 2023, then jumped by 335.22% to $30.4 million in 2024, then sank by 63.11% to $11.2 million in 2025, then slumped by 44.37% to $6.2 million in 2026.
• The last three Accumulated Expenses figures came in at $6.2 million (Q1 2026), $11.2 million (Q4 2025), and $45.3 million (Q3 2025), per Business Quant data.